Related Searches: Tea Vitamin Nutrients Ingredients paper cup packing

Food & Health Ingredients
Health & Nutrition
Processing & Packaging
Starch & Starch Derivatives
You are here: Home >news >Indena: Meriva curcumin can improve health of NAFLD sufferers

Indena: Meriva curcumin can improve health of NAFLD sufferers

2017-06-14 ingredientsnetwork

Tag: Curcumin NAFLD sufferers

Share       

A recent randomized controlled clinical trial has shown that the administration of Indena’s bioavailable curcumin formulation, Meriva, may improve the health status in subjects with non-alcoholic fatty liver disease (NAFLD), as assessed by multiple liver parameters. This is the first clinical study investigating the effects, efficacy and safety of curcumin phytosome supplementation in fatty liver disorders.

The study aimed to assess the effects on metabolic profile in subjects with NAFLD.. Eighty seven subjects diagnosed with grades 1-3 (according to liver sonography) were enrolled and randomly assigned to curcumin (1000 mg per day in 2 divided doses) (n = 44) or control (n = 43) group for a period of 8 weeks. Supplementation with Meriva was associated with reductions in BMI (P = 0.003) and waist circumference (P < 0.024). Consistent with the findings of liver ultrasonography, serum levels of AST and ALT were reduced by the end of trial in the curcumin group (respectively from 35.46±22.97 to 24.85±12.84 and from 27.63±11.35 to 20.68±6.65, P < 0.001) but elevated in the placebo group (respectively from 36.81±24.32 to 41.33±23.97 and from 27.44±10.01 to 31.23±12.80, P < 0.001). The effect of curcumin in reducing serum AST (P < 0.001) and ALT (P < 0.001) levels was also significant in the between-group comparison. Likewise, ultrasonographic findings improved in 75% of subjects in the curcumin group while the rate of improvement in the control group was 4.7% (P < 0.001)

Furthermore, supplementation with Meriva was associated with a reduction of serum levels of total cholesterol (P < 0.001), LDL cholesterol (P < 0.001), triglycerides (P < 0.001), non-high density lipoprotein cholesterol (P < 0.001), and uric acid (P < 0.001).

No safety and tolerability issues were reported during the 8 weeks of treatment.

“Non-Alcoholic fatty liver disease is the most common chronic liver disorder in the Western Countries, affecting 30% of the general adult population, up to 60-70% in diabetic and obese patients,” said Antonella Riva, Product Research Manager at Indena. “This is the first clinical study investigating the effects of Meriva in improving liver health; the positive results we obtained show that our bioavailable curcumin formulation may help to improve the health status in these subjects. Our commitment in Research and Development drives us to explore important goals to fulfil the unmet and increasing health needs deriving from modern life style conditions”.

E-newsletter

Subscribe to our e-newsletter for the latest food ingredients news and trends.

Tags

SJGLE B2B Website : 中文版 | ChineseCustomer Service: 86-400 610 1188-3 ( Mon-Fri 9: 00-18: 00 BJT)

About Us|Contact Us|Privacy Policy|Intellectual Property Statement

Copyright 2006-2023 Shanghai Sinoexpo Informa Markets International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-121  沪公网安备31010402001403号

Inquiry Basket

Inquiry Basket

Buyer service

Buyer service

Supplier service

Supplier service

Top

Top